Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Primary tabs
View
(active tab)
Oncolys BioPharma
February 21, 2018
Merck & Co makes biggest oncolytic virus bet since Amgen in 2011
July 23, 2013
In licensing, you don’t always get what you pay for
September 11, 2012
Geron blow could put final nail in telomerase inhibitor coffin
November 26, 2010
Deal activity dims in HIV
May 14, 2010
Avexa’s partnering problems could be contagious in HIV space
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
February 26, 2019
Vantage Pharma, Biotech and Medtech 2018 in Review
Editor's Picks
September 05, 2019
Esmo 2019 preview – Parps on parade
September 10, 2019
Alzheimer's setbacks have prompted $39bn of market cap losses this year
September 12, 2019
Should the diabetes development road end for Sanofi?
August 27, 2019
Six burning Otezla questions
August 29, 2019
The PCSK9 wars continue, but at what cost?
